GlassScriptPhysician profile
Michael L Faber
NPI 1245325927
$1,310.97
in general payments reported to CMS, 2019-2025
21 companies · $180 in 2025
The $180 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.70 · 2020: $200 · 2021: $279 · 2022: $269 · 2023: $166 · 2024: $167 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $511.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $337.36 | 2020-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $189.66 | 2020-2024 | Jardiance, Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.46 | 2021-2025 | Jardiance |
| Idorsia Pharmaceuticals US INC | $95.55 | 2022-2023 | Quviviq |
| Kiniksa Pharmaceuticals, LTD. | $72.50 | 2021-2022 | |
| Glaxosmithkline, LLC. | $68.79 | 2023-2025 | Trelegy Ellipta, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.49 | 2019-2021 | |
| Amarin Pharma, INC. | $48.78 | 2020-2021 | |
| Pfizer INC. | $43.04 | 2023-2024 | |
| Vivus LLC | $42.60 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $26.48 | 2019 | |
| Merck Sharp & Dohme LLC | $26.41 | 2020-2021 | |
| Exact Sciences Corporation | $19.22 | 2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $18.55 | 2020 | |
| Abbott Laboratories | $18.17 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $17.09 | 2025 | Cds - Mct/Cem Monitoring |
| Biohaven Pharmaceuticals, INC. | $16.19 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.40 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.21 | 2024 | Eliquis |
| Alnylam Pharmaceuticals INC. | $12.30 | 2022 | |
| Mannkind Corporation | $11.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Faber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.